Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

[1]  T. Miyamoto,et al.  Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome , 2020, Hematological oncology.

[2]  N. Schmitz,et al.  Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation , 2019, Bone Marrow Transplantation.

[3]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[4]  S. Montoto,et al.  Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party , 2018, British journal of haematology.

[5]  S. Montoto,et al.  Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties , 2018, Bone Marrow Transplantation.

[6]  M. Weichenthal,et al.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.

[7]  D. Weisdorf,et al.  Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era , 2016, Bone Marrow Transplantation.

[8]  Ash A. Alizadeh,et al.  Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study , 2016 .

[9]  J. Briones,et al.  Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Wilcox.  Cutaneous B‐cell lymphomas: 2016 update on diagnosis, risk‐stratification, and management , 2016, American journal of hematology.

[11]  H. Shimizu,et al.  Allogeneic hematopoietic stem cell transplantation following reduced‐intensity conditioning for mycosis fungoides and Sezary syndrome , 2016, Hematological oncology.

[12]  Y. Oki,et al.  Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Duvic,et al.  Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. , 2015, Clinical lymphoma, myeloma & leukemia.

[14]  J. Jorgensen,et al.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. , 2015, Blood.

[15]  N. Schmitz,et al.  Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Alan M. Miller,et al.  ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME , 2014, Bone Marrow Transplantation.

[17]  O. Dereure,et al.  Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas , 2014, Haematologica.

[18]  J. Scarisbrick,et al.  A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. , 2013, European journal of cancer.

[19]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Schmitz,et al.  Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Wei Wei,et al.  Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  S. Devesa,et al.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.

[24]  N. Schmitz,et al.  Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  N. Schmitz,et al.  Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma , 2008, Bone Marrow Transplantation.

[26]  Nicola Pimpinelli,et al.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.

[27]  R. Jones,et al.  Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides , 2007, Bone Marrow Transplantation.

[28]  L. Duncan.  Cutaneous B-cell Lymphomas , 2006 .

[29]  A. Nademanee,et al.  Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Prince,et al.  Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[31]  T. Kuzel,et al.  Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect , 2000, Bone Marrow Transplantation.

[32]  M. Weinstock,et al.  Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. , 1999, American journal of public health.

[33]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[34]  P. Bunn,et al.  Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. , 1979, Cancer treatment reports.